NASDAQ:CEMI

Chembio Diagnostics Stock Forecast, Price & News

$3.61
-0.13 (-3.48 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.58
Now: $3.61
$3.73
50-Day Range
$3.40
MA: $4.31
$5.65
52-Week Range
$3.01
Now: $3.61
$15.89
Volume666,598 shs
Average Volume4.93 million shs
Market Capitalization$72.86 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Chembio Diagnostics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135
Employees324
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.46 million
Book Value$1.37 per share

Profitability

Net Income$-13,680,000.00

Miscellaneous

Market Cap$72.86 million
Next Earnings Date5/3/2021 (Estimated)
OptionableNot Optionable

Headlines

Chembio Diagnostics's Earnings Outlook
March 10, 2021 |  benzinga.com
CEMI Jan 2021 5.000 call
January 16, 2021 |  in.finance.yahoo.com
CEMI Jan 2021 12.500 put
January 16, 2021 |  in.finance.yahoo.com
Is Chembio Diagnostics (NASDAQ:CEMI) Using Too Much Debt?
December 5, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.27 out of 5 stars

Medical Sector

854th out of 2,024 stocks

Pharmaceutical Preparations Industry

402nd out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$3.61
-0.13 (-3.48 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

Is Chembio Diagnostics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Chembio Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CEMI, but not buy additional shares or sell existing shares.
View analyst ratings for Chembio Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than Chembio Diagnostics?

Wall Street analysts have given Chembio Diagnostics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chembio Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Chembio Diagnostics
.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) posted its quarterly earnings data on Wednesday, March, 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.07. The business earned $10.23 million during the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 73.70% and a negative net margin of 76.55%.
View Chembio Diagnostics' earnings history
.

How has Chembio Diagnostics' stock price been impacted by Coronavirus?

Chembio Diagnostics' stock was trading at $3.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CEMI stock has increased by 16.5% and is now trading at $3.61.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CEMI?

5 Wall Street analysts have issued twelve-month price targets for Chembio Diagnostics' stock. Their forecasts range from $4.00 to $10.00. On average, they anticipate Chembio Diagnostics' stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 100.8% from the stock's current price.
View analysts' price targets for Chembio Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the following people:
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 53, Pay $346.94k)
  • Mr. Javan Esfandiari, Exec. VP, Chief Science & Technology Officer (Age 54, Pay $409.98k)
  • Mr. Richard L. Eberly, Pres, CEO & Director (Age 60)
  • Mr. Paul J. Angelico, VP of Global Operations
  • Mr. Charles Caso, VP of Sales & Marketing
  • Dr. Konstantin Lyashchenko, Research Director of Chembio Diagnostic Systems Inc

Who are some of Chembio Diagnostics' key competitors?

What other stocks do shareholders of Chembio Diagnostics own?

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Penbrook Management LLC (1.04%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari and John Gary Potthoff.
View institutional ownership trends for Chembio Diagnostics
.

Which major investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including Penbrook Management LLC.
View insider buying and selling activity for Chembio Diagnostics
or view top insider-selling stocks.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $3.61.

How much money does Chembio Diagnostics make?

Chembio Diagnostics has a market capitalization of $72.86 million and generates $34.46 million in revenue each year. The company earns $-13,680,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Chembio Diagnostics have?

Chembio Diagnostics employs 324 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is www.chembio.com.

Where are Chembio Diagnostics' headquarters?

Chembio Diagnostics is headquartered at 555 WIRELESS BLVD., HAUPPAUGE NY, 11788.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.